Phase 2 N=24 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Refractory Follicular Lymphoma · Relapsed Follicular Lymphoma
Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
Phase 4 N=8 Pharmacokinetics of JULUCA in Hemodialysis
HIV/AIDS · ESRD
Primary: Dolutegravir (DTG) Ctau — 1259; 1666 ng/mL
Phase 3 N=282 Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants
N/A N=4 Imagine to Remember: Improving Medication Adherence in Pre- and Type 2 Diabetes
Medication Adherence
Primary: Medication Adherence — 34; 42 percent change — p=0.0002
N/A N=44 Mechanisms Underlying Local and Systemic Effects of Massage
Muscle Atrophy
Primary: Percent Change in Myofiber Cross Sectional Area (CSA). — -15.1; -13.4 percent change from baseline
N/A N=4 Direct Comparison of Spinal Cord Stimulator Parameter Settings
Spinal Cord Stimulation · High-frequency Stimulation · High-density Stimulation
Primary: Visual Analog Pain Scale — 2.29; 6.31 units on a scale
Phase 2 N=15 Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
Phase 3 N=351 Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Axillary Hyperhidrosis
Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…
N/A N=40 QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
Smoking · Smoking Cessation · Craving
Primary: Questionnaire on Smoking Urges Administered Daily Pre TMS to Measure Craving — 16; 12 units on a scale
N/A N=45 Effects of Electrotherapy on Pain, Anxiety, Motion and Disability in Adults With Neck or Upper Body Pain.
Chronic Pain
Primary: Decrease in Chronic Subclinical Neck or Upper Quadrant Pain — 0; 2.0; 2.0 cm
Phase 2 N=44 Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Safety Outcome — 1; 3; 9; 6 Participants
Phase 2 N=58 Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
Shigella
Primary: Number of Participants With Moderate-Severe Shigellosis Illness, With Challenge — 14; 17 Participants
N/A N=119 A Pilot Peer Mentor Intervention That Trains Black Men Who Have Sex With Men (BMSM) to Use and Promote Uptake of HIV/STI Self-Testing to Peers and Sex Partners: STAR Study (Self-Testing at Your Residence)
HIV/AIDS · Sexually Transmitted Diseases
Primary: Session Attendance — 64; 55 Participants
Phase 2 N=24 Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
Parkinson Disease
Primary: Change From Baseline in MDS-UPDRS Part II. — 10.00; 7.33; -1.87; 0.11 score on a scale (52 points total)